four-parameter sigmoidal (logistic) model (graphpad prism 7) Search Results


prism 7 curve fitting  (GraphPad Software Inc)
90
GraphPad Software Inc prism 7 curve fitting
Prism 7 Curve Fitting, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism 7 curve fitting/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism 7 curve fitting - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
four-parameter non-linear regression analysis software  (GraphPad Software Inc)
90
GraphPad Software Inc four-parameter non-linear regression analysis software
Four Parameter Non Linear Regression Analysis Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/four-parameter non-linear regression analysis software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
four-parameter non-linear regression analysis software - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
prism 7 software  (GraphPad Software Inc)
90
GraphPad Software Inc prism 7 software
Prism 7 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism 7 software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism 7 software - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
non-linear regression graphpad prism 7 four-parameter model  (GraphPad Software Inc)
90
GraphPad Software Inc non-linear regression graphpad prism 7 four-parameter model
Non Linear Regression Graphpad Prism 7 Four Parameter Model, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/non-linear regression graphpad prism 7 four-parameter model/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
non-linear regression graphpad prism 7 four-parameter model - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
graphpad prism 7.04  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prism 7.04
Graphpad Prism 7.04, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism 7.04/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism 7.04 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
four-parameter sigmoidal (logistic) model (graphpad prism 7)  (GraphPad Software Inc)
90
GraphPad Software Inc four-parameter sigmoidal (logistic) model (graphpad prism 7)
Four Parameter Sigmoidal (Logistic) Model (Graphpad Prism 7), supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/four-parameter sigmoidal (logistic) model (graphpad prism 7)/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
four-parameter sigmoidal (logistic) model (graphpad prism 7) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
graphpad prism7 software  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prism7 software
Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad <t>Prism7</t> software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.
Graphpad Prism7 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism7 software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism7 software - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
four-parameter variable slope regressions graphpad prism 7  (GraphPad Software Inc)
90
GraphPad Software Inc four-parameter variable slope regressions graphpad prism 7
Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad <t>Prism7</t> software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.
Four Parameter Variable Slope Regressions Graphpad Prism 7, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/four-parameter variable slope regressions graphpad prism 7/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
four-parameter variable slope regressions graphpad prism 7 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
graphpad prism 7.05  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prism 7.05
Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad <t>Prism7</t> software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.
Graphpad Prism 7.05, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism 7.05/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism 7.05 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
prism 7.04 software  (GraphPad Software Inc)
90
GraphPad Software Inc prism 7.04 software
Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad <t>Prism7</t> software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.
Prism 7.04 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism 7.04 software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism 7.04 software - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
graphpad prism 7.02  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prism 7.02
Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad <t>Prism7</t> software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.
Graphpad Prism 7.02, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism 7.02/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism 7.02 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
variable slope model graphpad prism 7.02  (GraphPad Software Inc)
90
GraphPad Software Inc variable slope model graphpad prism 7.02
Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad <t>Prism7</t> software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.
Variable Slope Model Graphpad Prism 7.02, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/variable slope model graphpad prism 7.02/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
variable slope model graphpad prism 7.02 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad Prism7 software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.

Journal: Scientific Reports

Article Title: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents

doi: 10.1038/s41598-019-39510-w

Figure Lengend Snippet: Impact of 1 and 2 compounds on BT474 breast cancer cells. ( A ) To assess whether 1 and 2 could trigger cytotoxic effects on living cells, BT474 cells were treated with serial dilutions of 1 and 2 (or sterile DMSO). After three days, live cells were detected by standard MTT assay, highlighting the appearance of cytotoxic effects above 75 μM for compound 1 . Compound 2 did not show cytotoxic effects even at 250 μM. ***p < 0.001; ****p < 0.0001. ( B ) 1 and 2 compounds inhibit cell proliferation of BT474 and ( C ) SKBR3 breast cancer cell lines. Cells were treated with different concentration of the 1 and 2 and proliferation was assayed three days later by performing MTT assay. Results were fitted with four-parameter dose-response curve using GraphPad Prism7 software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01. ( D ) SKH100 Trastuzumab-resistant cells were treated with Trastuzumab (100 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses. After three days, live cells were detected by standard MTT assay. Data are represented as mean ± SD. *p < 0.05, **p < 0.01.

Article Snippet: Results were fitted with four-parameter dose-response curve using GraphPad Prism7 software. ( D ) EC50 values for 1 and 2 in BT474 and SKBR3 breast cancer cell lines are represented as histogram with 95% confidence intervals. ( E ) SKBR3 cells were treated with Trastuzumab (25 μg/ml) either alone or in combination with compound 1 or 2 at the indicated doses.

Techniques: MTT Assay, Concentration Assay, Software